Dupilumab in CRSsNP

NCT04678856 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis Without Nasal Polyps
Sinusitis
Chronic Sinusitis
Sinus Disorder
Respiratory Disorder

Interventions

DRUG: Dupilumab SAR231893
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]